Welcome!
Welcome to the website of the Dutch Snapshot Research Group (DSRG): a national surgical network aiming to initiate and coordinate large-scale collaborative research projects using the Snapshot study design in the Netherlands. Our network currently consists of 688 surgeons, radiologists, radiation oncologists, surgical residents, PhD students, physician assistants and research nurses employed in 75 out of 76 Dutch hospitals. Since 2016, thirtytwo articles were published by the DSRG.
On this website, more information about the DSRG, its projects, and publications can be found. Instructions on how to submit new research ideas are listed under ‘New research ideas’. READ MORE
NEWS
24 March 2022
First publication Snapshot rectal cancer 2.0
The first Snapshot study of the second rectal cancer cohort has been recently published in Colorectal Disease. This study evaluated the implementation of the new definition of rectal cancer in the Netherlands and performed a quality assessment of the sigmoid take-off training. Eighty-six collaborators participated and only half of the represented hospitals have implemented the new definition in their multidisciplinairy meetings. Before and after the training the collaborators were asked to classify 20 tumours on MRI. The agreement with the expert reference improved from 53% to 70%. This improvement highlights the added value of a training in implementation of radiological landmarks.
Many thanks to all collaborators!
NEWS
28 February 2022
First publication FANCY study
The first Snapshot study on selective histopathology following cholecystectomy has been recently published in the British Journal of Surgery. This multicenter prospective cross-sectional study investigated a selective approach for histopathological examination following cholecystectomy, decided by the judgement of the surgeon. In case of selective policy, 7846 of the 10041 gallbladders (78.1%) would have been held back from histopathological examination. Seven patients with a malignancy would have been missed, but would not have benefitted from these clinical consequences and two patients would have avoided harm of further treatment. Estimated cost savings would be 703.500 euros per 10.000 patients. Therefore, it can be concluded that histopathological examination is oncologically safe and could reduce costs.
Many thanks to all collaborators!